News & Events

• October 27, 2022
  

  C-Path Appoints Neuropharmacology Expert as New Vice President – Rare and Orphan Disease Programs

  C-Path today announced the appointment of Collin Hovinga, Pharm.D., MS, FCCP as Vice President for its Rare and Orphan Disease Programs, and lead for both its Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) initiative and Critical Path for Rare Neurodegenerative Diseases (CP-RND) public-private partnership. RDCA-DAP focuses on rare disease data sharing and accelerating therapy development. CP-RND focuses on the accelerating the development of therapies for patients living with rare neurodegenerative diseases, including ALS.

• October 20, 2022
  

  C-Path’s Ramona Walls Promoted to Executive Director of Data Science

  C-Path has named Ramona L. Walls, Ph.D., as Executive Director of Data Science within C-Path’s Data Collaboration Center (DCC).

• October 20, 2022
  

  C-Path and Sturge-Weber Foundation Announce Data Sharing Agreement to Support Treatment Development for Sturge-Weber Syndrome

  TUCSON, Ariz., October 20, 2022 — Critical Path Institute (C-Path) and the Sturge-Weber Foundation today announced a joint collaboration to incorporate patient data for Sturge-Weber syndrome (SWS) into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®). SWS is a highly variable, rare vascular disorder, including congenital facial marks, abnormal blood vessels in the brain,......
• October 13, 2022
  

  C-Path’s Transplant Therapeutics Consortium Receives EMA Draft Qualification Opinion for iBox Scoring System

  C-Path announced today that its Transplant Therapeutics Consortium (TTC) received a draft qualification opinion for the iBox Scoring System as a novel secondary efficacy endpoint for kidney transplant trials. This was achieved through the European Medicines Agency’s (EMA) qualification of novel methodologies for drug development.

• October 6, 2022
  

  C-Path to Lead Pre-Consortium Aimed at Transforming, Accelerating Medical Product Development in Alpha-1 Antitrypsin Deficiency

  C-Path today announced that it has recently launched a pre-consortium collaboration with the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER), focused on accelerating medical product development in alpha-1 antitrypsin deficiency (AATD). The FDA announced the pre-consortium today in a statement on its website.